Powering Precision
Scientific presentations to further validate the utility of Signatera in multiple tumor types
-
Ekaterina Kalashnikova, PhDNatera
-
Lung Cancer: Minimal residual disease (MRD) detection by ctDNA in relation to radiographic disease progression in patients with stage I-III non-small cell lung cancer (NSCLC) treated with definitive radiation therapy.
Emily Lebow, MDMemorial Sloan Kettering Cancer Center -
Sarcoma: Circulating Tumor DNA (ctDNA) detection of Molecular Residual Disease (MRD) as a Potential Biomarker in localized Soft Tissue Sarcoma (STS)
Abdulazeez Salawu, PhDPrincess Margaret Cancer Centre and Mount Sinai Hospital
-
Merkel Cell: Circulating tumor DNA to measure Merkel cell carcinoma tumor burden and detect early recurrence
Richa Rathore, PhDNatera -
Metastatic Renal: Monitoring Efficacy of Neoadjuvant Sunitinib in Metastatic Renal Cell Carcinoma using a Personalized and Tumor Informed ctDNA Assay
Christine B. Peterson, PhDDepartment of Biostatistics, MD Anderson Cancer Center -
Colon Cancer: A Single-arm Phase II Study to Evaluate Treatment with Gevokizumab in Patients with Stage II/III Colon Cancer who remain ctDNA+ after Curative Surgery and Adjuvant Chemotherapy
Thomas George, MDDirector of the GI Oncology Program, University of Florida
-
Colon Cancer: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US): NRG-GI008
N. Arvind Dasari, MDAssociate Professor Dept of Gastrointestinal Medical Oncology, MD Anderson Cancer Center -
Immunotherapy: External validation of the VIGex gene-expression signature (GES) as a novel predictive biomarker for immune checkpoint treatment (ICT).
Alberto Hernando-CalvoDivision of Medical Oncology and Hematology, Princess Margaret Cancer Centre
Natera led an Industry Expert Theater on June 5
We invite you to join us as we take a closer look how a personalized approach to molecular residual disease (MRD) assessment may be used to address the challenges many physicians face when determining next steps for their cancer patients. Is there a more reliable method to monitor my at-risk patients? Which patients should get adjuvant treatment?
Natera’s Oncology Portfolio
A single tissue source upfront provides a comprehensive genomic profile
*Reinert T, Henriksen TV, Christensen E, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer. JAMA Oncol. 2019
Learn about Signatera for your clinical trial
Well-designed and successful clinical trials help facilitate earlier “go/no go” decision-making. A trial with Signatera can ultimately enhance the R&D pipeline productivity and impact label expansion of approved oncology drugs to new treatment settings.
Why Partner with us?
-
Experienced team with Global reach: CE Mark, three FDA Breakthrough Device Designations, 8 Non-Significant Risk (NSR) determinations
-
>60 Natera IP assets covering ctDNA MRD and monitoring
-
Clinically validated across multiple solid tumors, Signatera has shown to predict relapse in >98% of patients without further treatment*